Gamco Investors INC. ET AL Has $2.94 Million Holdings in NeoGenomics, Inc. (NEO)

Gamco Investors INC. ET AL decreased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 5.2% in the 1st quarter, Holdings Channel reports. The firm owned 143,435 shares of the medical research company’s stock after selling 7,800 shares during the quarter. Gamco Investors INC. ET AL’s holdings in NeoGenomics were worth $2,935,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Crossmark Global Holdings Inc. bought a new stake in NeoGenomics in the 1st quarter valued at about $631,000. Texas Permanent School Fund purchased a new position in NeoGenomics during the 1st quarter valued at about $1,313,000. Comerica Bank purchased a new position in NeoGenomics during the 1st quarter valued at about $2,045,000. Candriam Luxembourg S.C.A. purchased a new position in NeoGenomics during the 1st quarter valued at about $2,725,000. Finally, Rhumbline Advisers grew its holdings in NeoGenomics by 190.6% during the 1st quarter. Rhumbline Advisers now owns 249,598 shares of the medical research company’s stock valued at $5,107,000 after buying an additional 163,698 shares in the last quarter. Hedge funds and other institutional investors own 74.71% of the company’s stock.

A number of research analysts have weighed in on NEO shares. BidaskClub raised NeoGenomics from a “hold” rating to a “buy” rating in a report on Tuesday, January 29th. Zacks Investment Research lowered NeoGenomics from a “buy” rating to a “hold” rating in a report on Saturday, March 2nd. CIBC raised NeoGenomics from a “neutral” rating to an “outperform” rating and reduced their target price for the company from $18.00 to $15.00 in a report on Tuesday, March 12th. Finally, Needham & Company LLC lifted their target price on NeoGenomics from $19.00 to $22.00 and gave the company a “buy” rating in a report on Friday, March 29th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $20.00.



Shares of NASDAQ NEO opened at $22.22 on Tuesday. NeoGenomics, Inc. has a 12 month low of $10.84 and a 12 month high of $23.85. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.35. The stock has a market cap of $2.18 billion, a PE ratio of 170.92 and a beta of 0.91.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, April 30th. The medical research company reported $0.05 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.03. The company had revenue of $95.60 million during the quarter, compared to analyst estimates of $89.71 million. NeoGenomics had a positive return on equity of 3.07% and a negative net margin of 0.14%. NeoGenomics’s revenue was up 50.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.04 earnings per share. Sell-side analysts anticipate that NeoGenomics, Inc. will post 0.19 EPS for the current year.

In other NeoGenomics news, EVP Steven C. Jones sold 14,621 shares of the company’s stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $19.24, for a total value of $281,308.04. Following the completion of the sale, the executive vice president now owns 241,815 shares of the company’s stock, valued at $4,652,520.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Robert J. Shovlin sold 186,014 shares of the company’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $18.96, for a total value of $3,526,825.44. Following the completion of the sale, the insider now directly owns 40,166 shares of the company’s stock, valued at approximately $761,547.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 602,400 shares of company stock valued at $12,693,858. 12.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://dakotafinancialnews.com/2019/05/14/gamco-investors-inc-et-al-has-2-94-million-holdings-in-neogenomics-inc-neo.html.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Read More: What is Cost of Debt?

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Institutional Ownership by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.